WO2005097421A9 - Methods for identifying risk of osteoarthritis and treatments thereof - Google Patents
Methods for identifying risk of osteoarthritis and treatments thereof Download PDFInfo
- Publication number
- WO2005097421A9 WO2005097421A9 PCT/US2005/010913 US2005010913W WO2005097421A9 WO 2005097421 A9 WO2005097421 A9 WO 2005097421A9 US 2005010913 W US2005010913 W US 2005010913W WO 2005097421 A9 WO2005097421 A9 WO 2005097421A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- osteoarthritis
- treatments
- methods
- identifying risk
- identifying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05763391A EP1729930A2 (en) | 2004-04-01 | 2005-03-31 | Methods for identifying risk of osteoarthritis and treatments thereof |
| CA002561669A CA2561669A1 (en) | 2004-04-01 | 2005-03-31 | Methods for identifying risk of osteoarthritis and treatments thereof |
Applications Claiming Priority (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55920304P | 2004-04-01 | 2004-04-01 | |
| US55904004P | 2004-04-01 | 2004-04-01 | |
| US55922504P | 2004-04-01 | 2004-04-01 | |
| US55904204P | 2004-04-01 | 2004-04-01 | |
| US55920204P | 2004-04-01 | 2004-04-01 | |
| US55927504P | 2004-04-01 | 2004-04-01 | |
| US55901104P | 2004-04-01 | 2004-04-01 | |
| US60/559,042 | 2004-04-01 | ||
| US60/559,202 | 2004-04-01 | ||
| US60/559,275 | 2004-04-01 | ||
| US60/559,203 | 2004-04-01 | ||
| US60/559,040 | 2004-04-01 | ||
| US60/559,225 | 2004-04-01 | ||
| US60/559,011 | 2004-04-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2005097421A2 WO2005097421A2 (en) | 2005-10-20 |
| WO2005097421A9 true WO2005097421A9 (en) | 2010-01-14 |
Family
ID=35125645
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2005/010912 Ceased WO2005100604A2 (en) | 2004-04-01 | 2005-03-31 | Methods for identifying risk of osteoarthritis and treatments thereof |
| PCT/US2005/010913 Ceased WO2005097421A2 (en) | 2004-04-01 | 2005-03-31 | Methods for identifying risk of osteoarthritis and treatments thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2005/010912 Ceased WO2005100604A2 (en) | 2004-04-01 | 2005-03-31 | Methods for identifying risk of osteoarthritis and treatments thereof |
Country Status (3)
| Country | Link |
|---|---|
| EP (2) | EP1729930A2 (en) |
| CA (2) | CA2561742A1 (en) |
| WO (2) | WO2005100604A2 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030114410A1 (en) | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
| CN110372795A (en) | 2007-08-02 | 2019-10-25 | 吉利德生物制剂公司 | LOX and LOXL2 inhibitor and its application |
| WO2010071405A1 (en) * | 2008-12-18 | 2010-06-24 | Erasmus University Medical Center Rotterdam | Markers for detecting predisposition for risk, incidence and progression of osteoarthritis |
| WO2010080769A2 (en) | 2009-01-06 | 2010-07-15 | Arresto Biosciences, Inc. | Chemotherapeutic methods and compositions |
| RU2012110585A (en) | 2009-08-21 | 2013-09-27 | Джилид Байолоджикс, Инк. | CATALYTIC DOMAINS OF LYSYLOXIDASE AND LOXL2 |
| JO3623B1 (en) | 2012-05-18 | 2020-08-27 | Amgen Inc | St2 antigen binding proteins |
| DK3456821T4 (en) | 2017-09-19 | 2024-04-15 | Deutsches Krebsforsch | NON-INTEGRATING DNA VECTORS FOR GENETIC MODIFICATION OF CELLS |
| WO2019210080A1 (en) * | 2018-04-25 | 2019-10-31 | The Regents Of The University Of California | Methods and compositions for skeletal and neurological disorders |
| CN112262213A (en) * | 2018-06-20 | 2021-01-22 | 富尔玛株式会社 | Novel anti-PAD 2 antibodies |
| EP3823989A2 (en) | 2018-07-16 | 2021-05-26 | Regeneron Pharmaceuticals, Inc. | Anti-il36r antibodies |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002366713A1 (en) * | 2001-12-20 | 2003-07-09 | Incyte Genomics, Inc. | Nucleotide polymorphisms associated with osteoarthritis |
-
2005
- 2005-03-31 CA CA002561742A patent/CA2561742A1/en not_active Abandoned
- 2005-03-31 WO PCT/US2005/010912 patent/WO2005100604A2/en not_active Ceased
- 2005-03-31 EP EP05763391A patent/EP1729930A2/en not_active Withdrawn
- 2005-03-31 WO PCT/US2005/010913 patent/WO2005097421A2/en not_active Ceased
- 2005-03-31 EP EP05768810A patent/EP1756317A4/en not_active Withdrawn
- 2005-03-31 CA CA002561669A patent/CA2561669A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1756317A2 (en) | 2007-02-28 |
| EP1756317A4 (en) | 2008-05-28 |
| WO2005097421A2 (en) | 2005-10-20 |
| EP1729930A2 (en) | 2006-12-13 |
| CA2561669A1 (en) | 2005-10-20 |
| CA2561742A1 (en) | 2005-10-27 |
| WO2005100604A8 (en) | 2006-03-09 |
| WO2005100604A2 (en) | 2005-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1835929B8 (en) | Anti-kir combination treatments and methods | |
| EP1740107A4 (en) | Electromagnetic treatment apparatus and method | |
| WO2005097421A9 (en) | Methods for identifying risk of osteoarthritis and treatments thereof | |
| AU2005316238B2 (en) | Cancer treatment method | |
| AU2004907262A0 (en) | Methods of treatment | |
| AU2004907263A0 (en) | Methods of treatment | |
| HK1115062A (en) | Methods for the treatment of substance abuse and dependence | |
| AU2004904399A0 (en) | Method of treatment | |
| AU2004905741A0 (en) | Method of treatment | |
| AU2004907137A0 (en) | Method of treatment | |
| AU2005902959A0 (en) | Method of treatment | |
| AU2005905222A0 (en) | Method of treatment | |
| AU2004907352A0 (en) | Methods of treating pain | |
| AU2004900546A0 (en) | Method of Treatment and Composition | |
| AU2005907121A0 (en) | Micro-identifiers and methods of application thereof | |
| HK1097275A (en) | Compounds and methods for treatment of cancer | |
| AU2004903941A0 (en) | Methods and Compositions for the Treatment of Hypogammaglobulinemia | |
| HK1121226A (en) | Anbrosteeone derivatives and method of use thereof | |
| AU2004900511A0 (en) | Compositions and Methods of Treatment | |
| AU2004904405A0 (en) | Compositions and Methods of Treatment | |
| AU2006901857A0 (en) | Method of treatment and agents useful for same | |
| AU2005902879A0 (en) | Mortgage plan and method of implementation | |
| AU2005906278A0 (en) | Method of data processing and representation | |
| HK1092700A (en) | Compounds and methods of use | |
| AU2005903854A0 (en) | Compositions and methods of treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2561669 Country of ref document: CA |
|
| NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2005763391 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 2005763391 Country of ref document: EP |